{"organizations": [], "uuid": "b4c7ce6463d037a0798c4f1fd7cd28189602afe1", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180419.html", "section_title": "Archive News &amp; Video for Thursday, 19 Apr 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-mithra-pharmaceuticals-announces-p/brief-mithra-pharmaceuticals-announces-positive-donesta-phase-iib-study-idUSFWN1RV0ZJ", "country": "US", "domain_rank": 408, "title": "BRIEF-Mithra Pharmaceuticals Announces Positive Donesta Phase IIb Study", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.22, "site_type": "news", "published": "2018-04-19T13:56:00.000+03:00", "replies_count": 0, "uuid": "b4c7ce6463d037a0798c4f1fd7cd28189602afe1"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-mithra-pharmaceuticals-announces-p/brief-mithra-pharmaceuticals-announces-positive-donesta-phase-iib-study-idUSFWN1RV0ZJ", "ord_in_thread": 0, "title": "BRIEF-Mithra Pharmaceuticals Announces Positive Donesta Phase IIb Study", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "vms", "sentiment": "none"}, {"name": "gdynia newsroom", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 19 (Reuters) - MITHRA PHARMACEUTICALS SA:\n* ANNOUNCES POSITIVE DONESTA PHASE IIB STUDY ACHIEVING PRIMARY OBJECTIVE AND CONFIRMING PROMISING SAFETY PROFILE\n* STUDY CONCLUDED THAT 15 MG OF E4 WAS OPTIMAL ORAL MINIMUM DOSE FOR EFFECTIVE TREATMENT OF VMS.\n* THIS DOSE COHORT DEMONSTRATES REDUCTION OF OVER 80% IN FREQUENCY OF MODERATE TO SEVERE VMS WHEN COMPARED TO BASELINE. Source text : bit.ly/2qKQ8h7 Further company coverage: (Gdynia Newsroom)\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.facebook.com/Reuters", "https://bit.ly/2qKQ8h7", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://www.linkedin.com/company/10256858/", "https://instagram.com/reuters/"], "published": "2018-04-19T13:56:00.000+03:00", "crawled": "2018-04-20T12:12:06.002+03:00", "highlightTitle": ""}